Award of NHS National Generics Pharmaceuticals Framework for Dasatinib and Paliperidone Injection

About

NHS England awarded a contract to Janssen-Cilag Ltd, Zentiva Pharma UK Ltd, Teva UK Limited, Mylan, and Mercury Pharmaceuticals Limited for the supply of Dasatinib and Paliperidone Injection under the NHS National Generics Pharmaceuticals framework.

The framework agreement has a total maximum duration of no more than 21 months, with an option to extend for a period or periods up to a total of 48 months at the Authority's discretion.

The contract value is AUD 27,009,807.

Call-offs under the framework include Dasatinib for CESW, LSNE, and NWLN regions from 01/05/2023 to 30/04/2024 (12 months each), and Paliperidone Injection for LSNE from 01/05/2023 to 31/05/2024 (13 months) and NWLN from 01/05/2023 to 31/01/2025 (21 months).